Evidence map›Paper›PMID 36106449›Full record

ArticleImmunology and cell biology2022

The effects of B-cell-activating factor on the population size, maturation and function of murine natural killer cells.

Pin Shie Quah, Vivien Sutton, Eden Whitlock, William A Figgett, Daniel M Andrews, Kirsten A Fairfax, Fabienne Mackay

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunology and cell biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Current status of BAFF targeting immunotherapy in B-cell neoplasm.International journal of clinical oncology · 2024
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Pin Shie QuahDepartment of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.ORCID 0000-0003-1684-5799
Vivien SuttonRosie Lew Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Eden WhitlockDepartment of Microbiology and Immunology, The University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
William A FiggettDepartment of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Daniel M AndrewsDepartment of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Kirsten A Fairfax *Blood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID 0000-0002-8394-137X
Fabienne Mackay *Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-6074-2693
The University of Melbourne · AUGarvan Institute of Medical Research · AUScope · GBThe University of Queensland · AUUniversity of Tasmania · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of B-cell-activating factor (BAFF) in B-lymphocyte biology has been comprehensively studied, but its contributions to innate immunity remain unclear. Natural killer (NK) cells form the first line of defense against viruses and tumors, and have been shown to be defective in patients with systemic lupus erythematosus (SLE). The link between BAFF and NK cells in the development and progression of SLE remains unstudied. By assessing NK cell numbers in wild-type (WT), BAFF

Indexed as

Lupus Erythematosus, SystemicTransmembrane Activator and CAML Interactor ProteinAnimalsInterleukin-4Killer Cells, NaturalMiceMice, TransgenicPopulation DensityInterleukin-4Transmembrane Activator and CAML Interactor ProteinAutoimmunityCancerImmunodeficiencyInnate immunityNatural killer cell

Identifiers

PMID36106449
PMCPMC9828838
OpenAlexW4295908375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.